AVTR — Avantor, Inc. stock price, charts and financials

QT79Avantor, Inc.

Avantor, Inc. (NYSE: AVTR) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
13.68
+0.01+0.07%
AVTRQT79Avantor, Inc.·NYSE
13.68+0.07%
TA
Loading chart...
Signal & projected range
Analyst consensus risingHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E-EPS (ttm)-0.84Insider Own1.92%Shs Outstand676.36MPerf Week10.14%
Market Cap9.25BForward P/E15.49EPS next Y0.88Insider Trans2.39%Shs Float658.05MPerf Month31.92%
Enterprise Value12.79BPEG-EPS next Q0.20Inst Own-Short Float8.51%Perf Quarter71.21%
Income-579.00MP/S1.41EPS this Y196.67%Inst Trans-Short Ratio5.75Perf Half Y23.58%
Sales6.56BP/B1.66EPS next Y8.79%ROA-4.98%Short Interest55.98MPerf YTD19.37%
Book/sh8.26P/C33.16EPS next 5Y7.97%ROE-10.34%52W High15.93 -14.12%Perf Year20.42%
Cash/sh0.41P/FCF32.32EPS past 3/5Y-ROIC-2.79%52W Low7.27 88.17%Perf 3Y-35.71%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-4.46% 0.49%Gross Margin31.83%Volatility5.11% 4.85%Perf 5Y-62.99%
Dividend TTM-EV/Sales1.95EPS Y/Y TTM-180.77%Oper. Margin-4.35%ATR (14)0.62Perf 10Y-
Dividend Ex-Date-Quick Ratio1.18Sales Y/Y TTM-3.29%Profit Margin-8.81%RSI (14)73.00Recom2.77
Dividend Gr. 3/5Y-Current Ratio1.78EPS Q/Q-12.50%SMA2016.44%Beta0.88Target Price10.73
Payout0.00%Debt/Eq0.71Sales Q/Q0.53%SMA5031.51%Rel Volume1.11Prev Close13.67
Employees13,500LT Debt/Eq0.70EarningsNov 04SMA20033.73%Avg Volume10.69MPrice13.68
IPO DateMay 17, 2019Option/ShortYes / YesEPS/Sales Surpr.9.65% 5.07%Net Debt/EBITDA-13.70Volume11,822,575Change0.07%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-30-26ReiteratedDeutsche BankHold$11$13
Jul-30-26ReiteratedRBC CapitalSector Perform$9.00$14
Jul-30-26ReiteratedMorgan StanleyEqual Weight$10$14
Jul-29-26ReiteratedJefferiesUnderperform$8.00$13
Jul-06-26ReiteratedEvercore ISI GroupIn Line$10$11
Jun-26-26ResumedBernsteinMarket Perform$25$11
Jun-24-26ReiteratedUBSNeutral$7.00$8.00
Jun-01-26ReiteratedWolfe Research$7.00
May-14-26ResumedRBC CapitalSector Perform$9.00
Mar-06-26DowngradeBarclaysEqual WeightUnderweight
Latest News
Aug-04-26
Aug-03-26
Jul-31-26
Jul-30-26
Jul-29-26
Jul-29-2603:04PM
Jul-23-26
Jul-22-26
Jul-21-26
Company

Avantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle East, and Africa, Avantor caters to a wide array of industries, including biopharmaceuticals, healthcare, educational institutions, government bodies, advanced technology firms, and applied materials enterprises. The company's extensive product portfolio features essential materials and consumables, such as high-purity chemicals and reagents, laboratory supplies, custom-formulated silicone materials, tailored excipients, single-use assemblies, process chromatography resins and columns, analytical sample preparation kits, educational and microbiology products, clinical trial kits, peristaltic pumps, and various fluid handling tips. Beyond consumables, Avantor also supplies advanced equipment and instrumentation. This range includes filtration and virus inactivation systems, incubators, analytical devices, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. Complementing its product offerings, Avantor delivers a suite of crucial services. These encompass on-site laboratory and production support, clinical services, equipment maintenance, comprehensive procurement and sourcing solutions, and specialized biopharmaceutical material scale-up and development expertise.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue6,5616,5526,7846,9677,5127,3866,3946,0405,864
Cost of Goods Sold Incl. D&A4,4734,4134,5044,6034,9104,8834,3134,1204,045
Gross Profit2,0892,1392,2792,3642,6032,5032,0811,9211,820
Selling, General and Administrative Excl. Other1,1971,5961,6411,5071,4731,5311,3741,3691,406
Research and Development
000000000
Other Operating Expense1,177790-44616000000
Operating Income-286-2461,0856961,130972707552414
Interest Expense178170219285266217308440524
Unusual Expense
Non-Operating Income (Expense)-7-25-12-1-13-2-337-71-3
Net Income Before Taxes-471-4418544118517536241-114
Income Taxes1058914289165180-543-27
Consolidated Net Income-579-53071232168757311738-87
Net Income From Continuing Operations-579-53071232168757311738-87
Net Income-579-53071232168757311738-87
EPS (Recurring)-0.84-0.781.050.481.020.860.09-0.84-0.72
EPS (Basic, Before Extraordinaries)-0.84-0.781.050.481.020.860.09-0.84-0.72
EPS (Diluted)-0.84-0.781.040.471.010.850.09-0.84-0.72
EBITDA201391,4781,0981,5221,350765880815
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio20.2648.5720.8849.58312.78
Price To Sales Ratio1.411.192.112.221.833.372.541.20
Gross Margin31.8432.6533.5933.9334.6533.8932.5531.8031.04
Operating Margin-4.36-3.7515.999.9915.0413.1611.069.147.06
Net Margin-8.82-8.0910.504.619.157.761.830.63-1.48
Shares Outstanding676678680676651591576401497
Market Capitalization9,2487,77014,32815,43313,73024,90516,2147,278
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$16.83$14.17$11.50$8.84$6.18 Close Price0.00M0.97M1.94M2.91M3.88MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
LUCIER GREGORY TDirectorMay 08 '26Buy8.3210,00083,20060,000May 11
Dingemans SimonDirectorMay 01 '26Buy8.1425,000203,50025,000May 05
MEHRA SANJEEV KDirectorMar 10 '26Buy8.01125,0001,001,250475,000Mar 11
LUCIER GREGORY TDirectorFeb 19 '26Buy9.1650,000458,00050,000Feb 23
SUMME GREGORY LDirectorFeb 12 '26Buy9.40100,000940,000400,000Feb 12
MEHRA SANJEEV KDirectorDec 05 '25Buy11.09350,0003,881,500350,000Dec 09
Ligner EmmanuelPresident and CEONov 17 '25Buy11.3587,500993,125283,424Nov 17
SUMME GREGORY LDirectorOct 30 '25Buy11.25100,0001,125,000300,000Oct 31
SUMME GREGORY LDirectorAug 21 '25Buy12.56100,0001,256,000200,000Aug 22
Eck Steven WSVP & Chief Accounting OfficerAug 05 '25Sale11.393,47639,59255,068Aug 06
SUMME GREGORY LDirectorMay 23 '25Buy12.5030,000375,000100,000May 27
SUMME GREGORY LDirectorMay 22 '25Buy12.6520,000253,00070,000May 22
SUMME GREGORY LDirectorMay 07 '25Buy12.0025,000300,00050,000May 09
Massaro Joseph RDirectorApr 29 '25Buy12.308,10099,63035,038Apr 29
SUMME GREGORY LDirectorApr 28 '25Buy12.5025,000312,50025,000Apr 29
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.